There is inconsistent evidence from previous studies on the association between ADRB2 polymorphisms and treatment response to inhaled β2-agonists on COPD exacerbations [6,7,8], short-term bronchodilator response (BDRs) [9,10], and long-term changes in forced expiratory volume in 1 s (FEV1) in patients with COPD [10]. Here, ADRB2 is linked to chronic obstructive pulmonary disease.